Kv1.3 inhibitors have differential effects on glucose uptake and AMPK activity in skeletal muscle cell lines and mouse ex vivo skeletal muscle

D Lee Hamilton, Craig Beall, Stewart Jeromson, Cyrille Chevtzoff, Daniel J Cuthbertson, Michael L J Ashford (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    8 Citations (Scopus)

    Abstract

    Knockout of Kv1.3 improves glucose homeostasis and confers resistance to obesity. Additionally, Kv1.3 inhibition enhances glucose uptake. This is thought to occur through calcium release. Kv1.3 inhibition in T-lymphocytes alters mitochondrial membrane potential, and, as many agents that induce Ca(2+) release or inhibit mitochondrial function activate AMPK, we hypothesised that Kv1.3 inhibition would activate AMPK and increase glucose uptake. We screened cultured muscle with a range of Kv1.3 inhibitors for their ability to alter glucose uptake. Only Psora4 increased glucose uptake in C2C12 myotubes. None of the inhibitors had any impact on L6 myotubes. Magratoxin activated AMPK in C2C12 myotubes and only Pap1 activated AMPK in the SOL. Kv1.3 inhibitors did not alter cellular respiration, indicating a lack of effect on mitochondrial function. In conclusion, AMPK does not mediate the effects of Kv1.3 inhibitors and they display differential effects in different skeletal muscle cell lines without impairing mitochondrial function.
    Original languageEnglish
    Pages (from-to)13-20
    Number of pages8
    JournalJournal of Physiological Sciences
    Volume64
    Issue number1
    Early online date17 Sep 2013
    DOIs
    Publication statusPublished - Jan 2014

    Keywords

    • Ampk
    • Glucose uptake
    • Kv1.3
    • Skeletal muscle

    Fingerprint Dive into the research topics of 'Kv1.3 inhibitors have differential effects on glucose uptake and AMPK activity in skeletal muscle cell lines and mouse ex vivo skeletal muscle'. Together they form a unique fingerprint.

  • Cite this